{"id":"tp-31825","type":"article-newspaper","title":"Vir Biotechnology Shares Rise Nearly 10% in Premarket After Gilead Deal","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/31825","datePublished":"2026-10-14T13:15:33.000Z","dateModified":"2026-10-14T13:15:33.000Z","language":"en","abstract":"Gilead will use Vir’s PRO-XTEN platform to discover and develop cancer drugs under an agreement valued at up to nearly $1.9 billion.","section":"Business","references":[]}